Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alba Therapeutics Corporation

http://www.albatherapeutics.com/

Latest From Alba Therapeutics Corporation

AgomAb Therapeutics Identifies Regenerative Pathway Modulators, Attracts Investors

Two US VCs have led a large $75m series B financing of Belgium’s AgomAb Therapeutics, which is gaining traction in developing antibodies that act on the HGF-MET pathway, potentially reversing fibrosis and allowing damaged tissues to regain function.

Regenerative Medicine Inflammation

How Sweden's Calliditas Built Up Its US Presence And Development Portfolio

Interview: delivering on its US business strategy during the COVID-19 pandemic has required a focus on communication, according to Calliditas CEO Renee Aguiar-Lucander.

Renal Business Strategies

Deal Watch: RedHill Finds New Partner For Movantik

Having licensed rights to Movantik from AstraZeneca in February, RedHill has now offloaded EU rights to Cosmo. Calliditas to obtain PBC candidate in bid to acquire Genkyotex.

Deals Business Strategies

Takeda Acquires Celiac Venture PvP For Up To $330m

Japanese firm exercises option after promising Phase I results in disorder with no approved drugs, in deal that builds out its celiac pipeline.

Japan Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Biotechnology
    • Large Molecule
UsernamePublicRestriction

Register